Drugs / LW402
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07546149 | Oct → Dec 2025 | — | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07556471 | May 2026 → Feb 2028 expected | vitiligo | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07186387 | May 2023 → Sep 2024 | atopic eczema | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06800157 | Feb 2023 → May 2024 | rheumatoid arthritis | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07370909 | Jan 2026 → Mar 2028 expected | atopic eczema | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LW402 | “LW402 Tablets” NCT07546149 ↗ |
| Route | Oral | “Oral tablets administered BID” NCT06800157 ↗ |